EUCTR2015-004494-33-DK进行中（未招募）1 期
Anti-IL-17, a possible new treatment for contact dermatitis?
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Main criteria for inclusion
- •Patients must be > 18
- •Have a known nickel allergy with at least a +2 reaction when challenged with nickel
- •Patients must have given their informed consent to the protocol and the clinical procedures
- •Be able to speak and understand Danish.
- •Main criteria for inclusion
- •Patients must be > 18
- •Have at least two known contact allergies
- •Moderate to severe dermatitis at inclusion
- •Failure to local anti-inflammatory treatment and to at least one systemic anti-inflammatory treatment
- •Patients must have given their informed consent to the protocol and the clinical procedures
- •Be able to speak and understand Danish
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Main criteria for exclusion
- •Patients who have received any local anti-inflammatory treatment 2 weeks prior to day 0
- •Patients who have received any systemic anti-inflammatory treatment 4 weeks prior to day 0
- •Patients who have received any other study medication 4 weeks prior to day 0
- •Dermatitis at the upper inner arm
- •Patients with clinically significant disorders
- •Patients with active TB/serious infections
- •Women of child-bearing potential must use effective contraception which includes IUD, oral, injected or implanted hormonal device, hormone patch, vaginal hormonal ring, sterilization, occlusive cap or condom with spermicidal cream. Post-menopausal women (> 12 months of amenorrhea) are allowed not to use contraception.
- •Patients who have received any weakened vaccines 6 weeks prior to day 0 or who are planning to receive a weakened vaccine during the study
- •Latex allergy
- •Main criteria for exclusion
- •Patients who have received any local anti-inflammatory treatment 2 weeks prior to day 0
- •Patients who have received any systemic anti-inflammatory treatment 4 weeks prior to day 0 Patients who have received any other study medication 4 weeks prior to day 0
- •Patients with clinically significant disorders
- •Patients with active TB/serious infections
- •Women of child-bearing potential must use effective contraception which includes IUD, oral, injected or implanted hormonal device, hormone patch, vaginal hormonal ring, sterilization, occlusive cap or condom with spermicidal cream. Post-menopausal women (> 12 months of amenorrhea) are allowed not to use contraception.
- •Patients who have received any weakened vaccines 6 weeks prior to day 0 or who are planning to receive a weakened vaccine during the study
- •Latex allergy
研究者
相似试验
Unknown
3 期
Anti-IL-17 a New Treatment for Contact DermatititisAllergic Contact DermatititsNCT02778711Tanja Todberg, MD20
进行中（未招募）
1 期
Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)Chronic rhinosinusitis with nasal polypsCTIS2023-505711-20-00Tartu University Hospital4
撤回
4 期
An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal UltrasoundPsoriasisNCT04488185Novartis Pharmaceuticals
进行中（未招募）
不适用
Mechanism of action study of anti-IL17 treatment in spondyloarthritis.MedDRA version: 16.1Level: LLTClassification code 10032155Term: Other inflammatory spondylopathiesSystem Organ Class: 100000004859MedDRA version: 16.1Level: LLTClassification code 10070759Term: SpondylopathySystem Organ Class: 100000004859SpondyloarthritisEUCTR2013-002709-79-NLAcademic Medical Center, Department of Rheumatology
招募中
2 期
se of Anti-IL-17 in patients with Covid-19 associated pneumoniaCoronavirus infection, unspecifiedCoronavirus infectionsSevere acute respiratory syndrome (SARS)Severe Acute Respiratory SyndromeB34.2C01.925.782.600.550.200C01.748.730RBR-5vpyh4Pesquisador